If you previously took part in an Ebola trial run by the Oxford Vaccine Group, you may be eligible to take part in a study looking at the long-term safety of the investigational Ebola vaccines that you received (Ad26.ZEBOV and MVA-BN-Filo).
The duration of this safety follow-up study is approximately 5 years (60 months) and includes the time you have already spent in the previous study for Ebola vaccines. Follow-up will involve brief telephone contact every 6 months where any relevant medical information will be collected. You may also be asked to visit the clinic at the start of the study and if there is a significant change in your general health.
Your participation in this study will allow important long-term safety information to be collected which is vital to the future development of these vaccines.
If you would like to find out more, you can contact us via:
This study is being run by the Oxford Vaccine Group, part of the University of Oxford and is funded by Crucell Holland BV.